依达拉奉治疗肌萎缩性侧索硬化的疗效观察

B. Nightingale
{"title":"依达拉奉治疗肌萎缩性侧索硬化的疗效观察","authors":"B. Nightingale","doi":"10.14740/jnr589","DOIUrl":null,"url":null,"abstract":"Amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, is fatal within 3 years of symptom onset. Both upper motor neurons and lower motor neurons are targeted. It is hypothesized that: edaravone is effective at managing ALS. This review article used a combination of secondary and primary research articles to gain a plethora of information to help test this hypothesis. Using PubMed, research articles were studied to identify important information. For the Introduction, both secondary and primary articles were used without a limitation on publication date. For the Results section, only primary articles were used which had to have been published no earlier than 2006. The Results section of this review helped to support the hypothesis that edaravone is effective at managing ALS. The most pivotal efficacy endpoint, the change in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised score, was positively influenced by edaravone over the placebo. This was shown to be statistically significant by use of analysis of variance, amongst other statistical tests. Secondary endpoints such as forced vital capacity and pinch strength were also analyzed, showing similar favorable results. From the clinical trials analyzed in this review, it is concluded that edaravone is sufficient in treating ALS. Edaravone is limited to a target population which could prove to be a problem. Future studies should explore this issue in hopes of expanding the treatment population of edaravone. J Neurol Res. 2020;10(5):150-159 doi: https://doi.org/10.14740/jnr589","PeriodicalId":16489,"journal":{"name":"Journal of Neurology Research","volume":"2004 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effect of Edaravone on Amyotrophic Lateral Sclerosis\",\"authors\":\"B. Nightingale\",\"doi\":\"10.14740/jnr589\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, is fatal within 3 years of symptom onset. Both upper motor neurons and lower motor neurons are targeted. It is hypothesized that: edaravone is effective at managing ALS. This review article used a combination of secondary and primary research articles to gain a plethora of information to help test this hypothesis. Using PubMed, research articles were studied to identify important information. For the Introduction, both secondary and primary articles were used without a limitation on publication date. For the Results section, only primary articles were used which had to have been published no earlier than 2006. The Results section of this review helped to support the hypothesis that edaravone is effective at managing ALS. The most pivotal efficacy endpoint, the change in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised score, was positively influenced by edaravone over the placebo. This was shown to be statistically significant by use of analysis of variance, amongst other statistical tests. Secondary endpoints such as forced vital capacity and pinch strength were also analyzed, showing similar favorable results. From the clinical trials analyzed in this review, it is concluded that edaravone is sufficient in treating ALS. Edaravone is limited to a target population which could prove to be a problem. Future studies should explore this issue in hopes of expanding the treatment population of edaravone. J Neurol Res. 2020;10(5):150-159 doi: https://doi.org/10.14740/jnr589\",\"PeriodicalId\":16489,\"journal\":{\"name\":\"Journal of Neurology Research\",\"volume\":\"2004 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neurology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/jnr589\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/jnr589","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

肌萎缩性侧索硬化症(ALS)是一种神经退行性疾病,在症状出现后3年内是致命的。上运动神经元和下运动神经元都是目标。假设依达拉奉对治疗渐冻症有效。这篇综述文章结合了次要和主要的研究文章来获得大量的信息来帮助检验这一假设。使用PubMed,研究文章被研究以识别重要信息。对于引言,次要和主要的文章都被使用,没有出版日期的限制。对于结果部分,只使用了不早于2006年发表的主要文章。本综述的结果部分有助于支持依达拉奉对治疗ALS有效的假设。最关键的疗效终点,肌萎缩性侧索硬化症功能评定量表修订评分的变化,受依达拉奉的积极影响大于安慰剂。通过使用方差分析和其他统计检验,这表明具有统计显著性。次要终点,如强制肺活量和夹紧强度也进行了分析,显示出类似的有利结果。从本综述分析的临床试验来看,依达拉奉治疗ALS是足够的。依达拉奉仅限于目标人群,这可能是一个问题。未来的研究应进一步探讨这一问题,以期扩大依达拉奉的治疗人群。中华神经科学杂志,2020;10(5):150-159 doi: https://doi.org/10.14740/jnr589
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Effect of Edaravone on Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, is fatal within 3 years of symptom onset. Both upper motor neurons and lower motor neurons are targeted. It is hypothesized that: edaravone is effective at managing ALS. This review article used a combination of secondary and primary research articles to gain a plethora of information to help test this hypothesis. Using PubMed, research articles were studied to identify important information. For the Introduction, both secondary and primary articles were used without a limitation on publication date. For the Results section, only primary articles were used which had to have been published no earlier than 2006. The Results section of this review helped to support the hypothesis that edaravone is effective at managing ALS. The most pivotal efficacy endpoint, the change in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised score, was positively influenced by edaravone over the placebo. This was shown to be statistically significant by use of analysis of variance, amongst other statistical tests. Secondary endpoints such as forced vital capacity and pinch strength were also analyzed, showing similar favorable results. From the clinical trials analyzed in this review, it is concluded that edaravone is sufficient in treating ALS. Edaravone is limited to a target population which could prove to be a problem. Future studies should explore this issue in hopes of expanding the treatment population of edaravone. J Neurol Res. 2020;10(5):150-159 doi: https://doi.org/10.14740/jnr589
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信